Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Utilization and cost of non-insulin glucose-lowering drugs in Australia from 2013 to 2023
Retatrutide produced 24.2% average weight loss at 48 weeks through triple receptor agonism (GIP/GLP-1/Glucagon), while Survodutide achieved 14.9-18.7% weight loss at 46 weeks through dual receptor agonism (GLP-1/Glucagon)
Participants were asked to complete the questionnaire according to their perceptions of their daily practice environment within their specialty, and not reflecting their own personal clinical practice
The answer to this might be out of my sphere of influence, but as someone who advocates for public health, I had to advocate through a resolution to draw attention to this important matter
In the STEP (Semaglutide Treatment Effect in People with obesity) trials, participants receiving semaglutide achieved an average weight loss of 15-20% over the course of 68 weeks
